Effect of 3-5 Years of Scheduled CEA and CT Follow-up to Detect Recurrence of Colorectal Cancer: FACS Randomized Controlled Trial.

Phase III Randomized, Placebo (PL)-controlled, Double-blind Study of Intravenous Calcium/Magnesium (CaMg) to Prevent Oxaliplatin-induced Sensory Neurotoxicity (sNT), N08CB: An Alliance for Clinical Trials in Oncology Study.

Maintenance Treatment with Capecitabine and Bevacizumab versus Observation after Induction Treatment with Chemotherapy and Bevacizumab in Metastatic Colorectal Cancer (mCRC) : The Phase III CAIRO3 Study of the Dutch Colorectal Cancer Group (DCCG).

Bevacizumab Continuation versus No Continuation after first-line Chemo-Bevacizumab Therapy in Patients with Metastatic Colorectal Cancer: a Randomized Phase III non-Inferiority Trial.

A Randomised Clinical Trial of Chemotherapy Compared to Chemotherapy in Combination with Cetuximab in KRAS wild-type Patients with Operable Metastases from Colorectal Cancer: The New EPOC study

FOLFOXIRI/Bevacizumab (Bev) versus FOLFIRI/Bev as 1st-line Treatment in Unresectable Metastatic Colorectal Cancer (mCRC) Patients (pts): Results of the Phase III TRIBE Trial by GONO group.

Randomized Comparison of FOLFIRI Plus Cetuximab versus FOLFIRI Plus Bevacizumab as 1st-line Treatment of KRAS Wild-type Metastatic Colorectal Cancer: German AIO Study KRK-0306 (FIRE-3).

Pharmacodynamic and Efficacy Analysis of the BRAF Inhibitor Dabrafenib (GSK436) in Combination with the MEK Inhibitor Trametinib (GSK212) in Patients with BRAF V600 Mutant Colorectal Cancer (CRC)

A Randomized, Placebo-Controlled, Phase 2 Study of Tivantinib (ARQ 197) in Combination With Cetuximab and Irinotecan as Second-line Therapy in Patients With KRAS Wild?Type Metastatic Colorectal Cancer (CRC).